Although mutations in for instance IDH1 and -2, COL2A1 and TP53 combined with aberrations in signalling pathways such as IHH/PTHrP, pRB and PI3K/mTOR have been identified as key molecular changes in chondrosarcoma [20], the development of novel targeted therapies has not yet been successful. The gene discussed is TP53; the disease is chondrosarcoma.